Cue Biopharma, Inc. (CUE) analyst actions
Rating and price-target actions on CUE in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CUE overview →
1 measured CUE analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme | Press release | +0.17% | +0.04% |
Keep exploring
More CUE: earnings → · SEC filings → · CUE overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Nevro Corp. (NVRO) | 253 | 0.00% | 49% |
| DarioHealth Corp. (DRIO) | 252 | 0.00% | 45% |
| DOVA PHARMACEUTICALS (DOVA) | 251 | -0.10% | 46% |
| Krystal Biotech, Inc. (KRYS) | 251 | +0.05% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.